NEW YORK, April 8, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Company
(NYSE: BMY), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN),
Illumina Inc. (NASDAQ: ILMN), and West Pharmaceutical Services,
Inc. (NYSE: WST). Private wealth members receive these notes ahead
of publication. To reserve complementary membership, limited
openings are available at:
http://www.AnalystsReview.com/register
--
Biogen Idec Inc. Analyst Notes
On March 31, 2014, Biogen Idec
Inc. announced that it will report its Q1 2014 financial results on
April 23, 2014, before the market
opens. According to the Company, it will also host a live webcast
on the same day at 8:00 a.m. ET to
discuss the results. The full analyst notes on Biogen Idec Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04082014/BIIB/report.pdf
--
Bristol-Myers Squibb Company Analyst Notes
On April 1, 2014, Bristol-Myers
Squibb Company announced that it will report its Q1 2014 financial
results on April 29, 2014. The
Company informed that its executives will also review the financial
information and will address inquiries from investors and analysts
during a conference call scheduled on the same day at 9:00 a.m. ET. The full analyst notes on
Bristol-Myers Squibb Company are available to download free of
charge at:
http://www.AnalystsReview.com/04082014/BMY/report.pdf
--
Regeneron Pharmaceuticals, Inc. Analyst Notes
On April 3, 2014, Regeneron
Pharmaceuticals, Inc. (Regeneron) reported that it has entered into
collaboration with NASA, Teachers College,
Columbia University and the STEM Education Leadership Center
of Rye, New York to create the
Hudson Valley STEM Teaching Fellowship. George D. Yancopoulos, M.D., Ph.D., Chief
Scientific Officer of Regeneron and President of Regeneron
Laboratories, stated, "Regeneron is all about using cutting-edge
science to understand biology and develop new drugs. We believe it
is important to raise the level of science education in our
communities to graduate students who are scientifically literate,
as from this soil will spring the scientists of tomorrow. We are
pleased to provide fellowships and mentorships to enable this new
teacher-training program, which builds on several other science
education programs sponsored by Regeneron." The full analyst notes
on Regeneron Pharmaceuticals, Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/04082014/REGN/report.pdf
--
Illumina Inc. Analyst Notes
On April 2, 2014, Illumina Inc.
(Illumina) announced the introduction of new products that can be
applied directly to the discovery and translation of genomic
variation in blood and tissues associated with cancer. According to
Illumina, the new product additions include TruSeq® RNA Access
Library Prep Kits, TruSight™ Myeloid Sequencing Panel, and New
BaseSpace® Core Apps. Commenting on the launch, Rick Klausner, M.D. Chief Medical Officer of
Illumina, stated, "The latest additions to our product portfolio
address the unique needs of oncology researchers. Our product
solutions now support library preparation of the low-input,
poor-quality archival tissue samples that are so valuable for
cancer research. We're accelerating the discovery of
cancer-associated variants with simple-to-use data analysis
solutions, including software tools that support the creation of
genotypic/phenotypic databases. Our goal is to expand the use of
NGS beyond basic research, delivering relevant oncological genomic
information to clinical researchers where it has the potential to
inform improvements in cancer care." The full analyst notes on
Illumina Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04082014/ILMN/report.pdf
--
West Pharmaceutical Services, Inc. Analyst
Notes
On April 3, 2014, West
Pharmaceutical Services, Inc.'s stock went up by 0.46%, closing at
$45.01. Over the past five-day
trading period, the Company's shares went up by 5.96%, compared to
the Dow Jones Industrial Average Index which went up by 1.90%
during the same five-day trading period. The full analyst notes on
West Pharmaceutical Services, Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/04082014/GILD/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review